Humalog Tempo Pen

Humalog Tempo Pen is a prefilled, subcutaneous injectable pen that delivers insulin lispro, a rapid‑acting insulin analog, in a ready‑to‑use solution. It is authorized for prescription use in the European Union and is designed for people with diabetes who require mealtime glucose control. The device provides a convenient, accurate dosing mechanism without the need for separate vials or syringes and reduces preparation time for patients.

Humalog Tempo Pen is indicated for the management of blood glucose in adults and children with diabetes.

- Type 1 diabetes mellitus requiring mealtime insulin. - Type 2 diabetes mellitus when rapid‑acting insulin is needed. - Prandial (mealtime) glucose control to cover carbohydrate intake. - Flexible dose adjustment based on meals and activity. - Transition from multiple daily injections to a prefilled pen system.

Adverse reactions to Humalog Tempo Pen are generally consistent with other rapid‑acting insulins and can be grouped by frequency.

Common: - Hypoglycemia (low blood glucose). - Redness, swelling, or pain at the injection site. - Lipodystrophy or lipoatrophy at injection sites. - Transient weight gain. - Headache.

Serious: - Severe hypoglycemia requiring assistance. - Allergic reactions such as rash, urticaria, or angioedema. - Anaphylaxis. - Hypokalemia. - Insulin‑induced edema.

When using Humalog Tempo Pen, several safety considerations should be observed.

- Monitor blood glucose regularly to avoid hypoglycemia. - Rotate injection sites to reduce lipodystrophy. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be altered. - Pregnancy and lactation status should be evaluated; the safety profile is not fully established. - Educate patients on recognizing signs of severe hypoglycemia. - Store the pen according to manufacturer instructions to maintain potency.

Humalog Tempo Pen can interact with other medicines, affecting glucose control or insulin action.

Avoid: - Other rapid‑acting insulins or concentrated insulin formulations that may cause stacking. - Beta‑blockers, which can mask hypoglycemia symptoms. - MAO inhibitors that may potentiate insulin’s effect.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Corticosteroids, which raise blood glucose levels. - Thiazide diuretics, which may affect potassium balance. - Alcohol, which can cause delayed hypoglycemia.